Icosema
Novo Nordisk\'s Fixed-Ratio Insulin Icodec + Semaglutide Combination
Icosema is Novo Nordisk\'s investigational fixed-ratio combination of insulin icodec (a once-weekly basal insulin) and semaglutide (a GLP-1 receptor agonist). By combining both in a single weekly injection, it aims to simplify diabetes management while providing the metabolic benefits of GLP-1 therapy alongside insulin\'s glucose-lowering power. Use the Shotlee app to track your current protocol and build baseline data for whatever comes next.
What Is Icosema?
Icosema is Novo Nordisk\'s investigational fixed-ratio combination of insulin icodec (a once-weekly basal insulin) and semaglutide (a GLP-1 receptor agonist). By combining both in a single weekly injection, it aims to simplify diabetes management while providing the metabolic benefits of GLP-1 therapy alongside insulin\'s glucose-lowering power.
Track your current protocol in Shotlee while this science evolves. Having clean historical data means you can compare outcomes with precision if you ever switch medications.
How It Works
Insulin Icodec
Semaglutide Component
- • GLP-1 receptor agonist
- • Appetite suppression
- • Weight management benefits
- • Log weight trends in Shotlee
Combination Advantage
- • Single weekly injection
- • Simplified regimen
- • Dual metabolic action
- • Monitor both effects in Shotlee
Why This Matters
Managing both insulin and GLP-1 therapy in a single weekly injection dramatically simplifies treatment for people with Type 2 diabetes. Tracking dose adherence and metabolic markers in Shotlee ensures you stay on top of your protocol.
Clinical Data
Multiple Phase 3 trials (COMBINE program) are evaluating Icosema in Type 2 diabetes populations.
Side Effects
- • Hypoglycemia (insulin component)
- • GI symptoms (semaglutide component)
- • Injection site reactions
- • Track all side effects in Shotlee
Vital Protocol FAQs
What is Icosema?
Icosema is a fixed-ratio combination of once-weekly insulin icodec and semaglutide in a single injection. It is designed for people with Type 2 diabetes. Track your insulin and GLP-1 protocols together in the Shotlee app.
Is Icosema approved?
Icosema is still in Phase 3 trials. Use Shotlee to track your current insulin and GLP-1 protocols while awaiting results.
Prepare for Better Protocol Outcomes
Track your protocol with Shotlee and make every decision from clean, visible data instead of guesswork.
🚀 Use Shotlee for Free